

Topical Collection

Cancers Precision Immunotherapy

Message from the Collection Editor

Precision immunotherapy refers to the field of matching immune therapies to a tumor's immunomic landscape in order for that tumor to be treated with immunotherapy in a "precise" manner. Because the immune environment of each tumor may be distinct, treating precisely appears to require a personalized/individualized immunotherapy approach. There are many innovative ways to address the immune deficits that allow tumors to grow. Some of the new and powerful tools in the therapeutic armamentarium include CAR T-cells, bispecific antibodies, personalized vaccines, immune checkpoint inhibitors and immune stimulatory molecules. Interrogating the tumor immunogram and matching the patient to the compounds that are most likely to reactivate the immune system and permit it to eliminate cancer cells requires multiple advanced molecular technologies. Even so, precision immunotherapy has shown a remarkable ability to eradicate even advanced malignancies.

Collection Editor

Prof. Dr. Razelle Kurzrock

Froedtert & The Medical College of Wisconsin Clinical Cancer Center,
Milwaukee, WI 53226, USA



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/129551

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)